The team discuss the NORD summit particularly FDA commissioner Scott Gottleib’s presentation, panel discussion on cell and gene therapy pricing as well as P4A’s lunch and learn on cell and gene therapy access – learnings from the EU.
Also in this episode, Novartis’ Kymriah innovative payment agreement in Italy, the changing evaluation trends for gene therapies among HTA bodies and Alliance for Regenerative Medicines’ Q3 report.
Presenter: Jack Rawson
Contributor: Sophie Schmitz
Producer: Aparna Krishnan
World EPA Conference 2024 Special
Rare Disease Day Special 2024: The Role of Genetic Diagnosis in Rare Conditions with Nick Meade
Celebrating 5 Years of P4A: Reflections on Rare Diseases, Cell and Gene Therapies, and Legislation in Europe
Revolutionizing Patient Outcomes: The Power of Digital Health Solutions with RJ Kedziora
The Future of Patient Engagement and the Role of Technology in Healthcare with Iola Forster
Navigating the New EU HTA Regulation and Its Impact on ATMP Development
Alejandro Dorenbaum, CMO of Reneo Pharmaceuticals Discusses Clinical-Stage Therapies
Interview with Xortx Therapeutics CEO, Dr Allen Davidoff discussing their journey from early development to potential launch
World EPA Congress 2023 Special
Rare Disease Day Special 2023
Trends to look out for in 2023
World Orphan Drug Congress Europe 2022 Special
Winds of change for German Healthcare Market!
Part 2 -Patient Empowerment: Is it a no-brainer?
Part 1 Patient Empowerment; Why involving patients from early drug development through to launch is a no-brainer!
What makes P4A an award winning consultancy?
Special Episode with EUCOPE-Part 2 with Alexander Natz
Special series with Eucope: Part 1 featuring Victor Maertens
China market access: obstacle or opportunity for orphan drug, cell and gene therapy manufacturers?
Should the Middle East be a priority launch market for orphan drug manufacturers?
Create your
podcast in
minutes
It is Free
Museum of the Missing
Strange by Nature Podcast
The Poetry of Science
Sasquatch Chronicles
Hidden Brain